Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Robert J. Motzer, Dmitry Nosov, Timothy Eisen, +17

Journal of Clinical Oncology

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

David Cella, Viktor Grünwald, Bernard Escudier, +10

The Lancet Oncology

Checkmate 214Patient-reported OutcomesOncologyUrologyGenitourinary Cancer +6

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Yohann Loriot, Kurt Miller, Cora N. Sternberg, +13

The Lancet Oncology

UrologyHealth-related QualityPain MedicineMedicineSkeletal-related Events +10

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Bertrand Tombal, Fred Saad, David F. Penson, +6

The Lancet Oncology

UrologyPatient-reported OutcomesMedicineClinical TrialsOutcomes Research +6

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

David Cella, Robert J. Motzer, Cristina Suárez, +9

The Lancet Oncology

UrologyPatient-reported OutcomesGenitourinary CancerMedicineCancer Management +7

Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial

D. Cella, Cristina Ivanescu, Stefan Holmström, +3

Annals of Oncology

Additional AnalysesUrologyOncologyCancer ManagementClinical Trials +4

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials

Fred Saad, Cristina Ivanescu, D. Phung, +5

Prostate Cancer and Prostatic Diseases

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, +10

European Urology

Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients

Arnold Degboe, Cristina Ivanescu, Jeffrey M. Rohay, +2

Supportive Care in Cancer

The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies

Tomasz M. Beer, Kurt Miller, Bertrand Tombal, +6

European Journal of Cancer

Quality Of LifeLife AssessmentUrologyHealth PolicyMedicine +10